We would love to hear your thoughts about our site and services, please take our survey here.
Excellent AGM, great questions from share holders and answered for any that still needed clarification.
I continually keep adding when I can. It’s opportunity I’m not willing to miss out on. It all adds up. Patience will pay off for long term holders. GLA
I agree Woland1. Dr Tap knows that ava6000 is delivering to the tumour and that dox will behave like dox and how effective that is. He will be encouraging patients to take part in the trial. I imagine some new trial patients will have less advanced cancer than the previous cohorts.
Phase 1 protocols are often amended to increase the cohort sample size, for example a strong efficacy signal may warrant pursuit of accelerated approval, in which case defining a clear termination to a small trial may not be desirable.
Dr Tap , I believe is confident AVA6000 is working based on what the data he has seen. I don’t think he is putting his neck on the line if he suggests to more of his patients that they participate on the trial.
Resolution 13 in the AGM explanatory notes . ( I will try and ask the question in a different way in the hope someone can answer)
A company may only purchase its own shares if authorised to do so by shareholders.
Does including this as a special resolution indicate that it avacta are considering buying back its own shares?
I’m better with the science than understanding the administration. I noticed on reading the AGM explanatory notice that reference to these special resolutions that include the phrases below , are these par the course or any info in it? I can’t find a previous note to compare.
The company does not intend to use further shares …
Preemptive offers resolution..
Share buy back resolution
https://avacta.com/wp-content/uploads/2023/06/23_0524-AGM-Notice-Notes-Explanatory.pdf
https://www.mordorintelligence.com/industry-reports/doxorubicin-market
North America is expected to dominate the market during the forecast period. The growing number of cancer cases and subsequently increasing usage of doxorubicin in mono and combination chemotherapies may impact the market.
The increasing number of mergers and acquisitions and partnerships for clinical trials with technologically advanced doxorubicin formulations are the crucial factors driving the market.
True icecool. I noticed Genbio license deal yesterday and up 30% in a day. Will happen here like that. I’mLTH and while it is uncomfortable to watch the SP drop, I’m resigned to the fact that I am invested in AIM and I have to accept the roller coaster ride. I keep adding when I can.
Very good read R. Thanks for sharing.
It says re the old mantra of derisking platforms is no longer the case.
“no evidence was found for the necessity to clinically de-risk a platform technology. On the contrary, about half of the platform companies were still preclinical at the time of the deal” phase 1b all important to include lots of data. Hmmm, just like our trial has been modified.